Riskpilot← Back to searchSign inGet full accessRoche Diagnostics Oy
OYActiveY-tunnus 1947409-7Revontulenpuisto 2-CWholesale of pharmaceutical and medical goods · NACE 4646Est. 200590 employees
Revenue 2025
EUR 45,9M
-4% vs 2024
EBITDA margin
8.8%
+9% vs 2024
Equity ratio
62.1%
Financial strength
Net profit 2025
EUR 1,7M
+47% vs 2024
| Revenue | EUR 45,9M | -4% |
| EBITDA | EUR 4M | +9% |
| Net profit | EUR 1,7M | +47% |
| Total assets | EUR 24,9M | +2% |
| Equity | EUR 15,5M | +13% |
| Employees | 90 | — |
Legal name
Roche Diagnostics Oy
Y-tunnus number
1947409-7
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9. helmikuuta 2005
Share capital
EUR 150 000
Employees
90 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääkkeiden ja kemiallisten tuotteiden myynti ja markkinointi sekä niihin liittyvä muu toiminta.
Address
Revontulenpuisto 2-C
Phone
+358010554511
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 59 855 | 51 260 | 0 | 47 648 | 45 872 |
| Staff expenses | −10 915 | −10 518 | −0 | −10 916 | −10 562 |
| EBITDA | 7 740 | 5 799 | 0 | 3 689 | 4 018 |
| Depreciation & amort. | −5 615 | −5 132 | −0 | −2 549 | −2 097 |
| EBIT | 2 125 | 667 | 1 811 | 1 140 | 1 921 |
| Net financials | −66 | −12 | 0 | 306 | 192 |
| Profit before tax | 2 695 | 968 | 0 | 1 446 | 2 113 |
| Tax | 569 | 113 | −0 | 262 | 377 |
| Net profit | 2 127 | 854 | 1 389 | 1 184 | 1 736 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 27 121 | 21 980 | 0 | 24 498 | 24 883 |
| Equity | 10 546 | 11 150 | 0 | 13 723 | 15 459 |
| Long-term debt | 1 245 | 975 | 0 | 0 | 0 |
| Short-term debt | 15 293 | 9 848 | 0 | 10 772 | 9 424 |
| Total debt | 16 575 | 10 830 | 0 | 10 772 | 9 424 |
EBITDA margin
8.8%
This company
15.8%
Market median
-44% vs market
20212025
Equity ratio
62.1%
This company
38.2%
Market median
+63% vs market
20212025
Return on equity
11.2%
This company
18.4%
Market median
+39% vs market
20212025
Net profit margin
3.8%
This company
8.1%
Market median
-53% vs market
20212025
Asset turnover
1.84×
This company
1.12×
Market median
+64% vs market
20212025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
JE Confidential Clerk | Confidential Clerk | 2017 |
DD Confidential Clerk | Confidential Clerk | 2026 |
JK Confidential Clerk | Confidential Clerk | 2023 |
PM Chief Executive Officer | Chief Executive Officer | 2024 |
EM Confidential Clerk | Confidential Clerk | 2026 |
AJ Confidential Clerk | Confidential Clerk | 2023 |
TM Confidential Clerk | Confidential Clerk | 2022 |
| Former (9) | ||
HM Confidential Clerk | Confidential Clerk | 2021 – 2022 |
PC | Audit | 2010 – 2023 |
NK Confidential Clerk | Confidential Clerk | 2021 – 2023 |
MB Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
TM Confidential Clerk | Confidential Clerk | 2017 – 2024 |
MB Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
TJ Chief Executive Officer | Chief Executive Officer | 2010 – 2020 |
HM Confidential Clerk | Confidential Clerk | 2023 – 2024 |
JJ Confidential Clerk | Confidential Clerk | 2017 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairperson | 2026 | |
| Board of Directors | 2025 | |
| Former (5) | ||
| Board of Directors | 2017 – 2019 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2019 – 2021 | |
| Chairperson | 2017 – 2021 | |
| Board of Directors | 2024 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Roche Diagnostics Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Heidi Marita Saanila-Sotamaa | Confidential Clerk | 0 companies |
| Jaana Elisabeth Mantere | Confidential Clerk | 0 companies |
| Dániel Dávid Noszek | Confidential Clerk | 0 companies |
| Petra Camilla Pörnull | Audit | 0 companies |
| Jari-Matti Kolari | Confidential Clerk | 0 companies |
| Patricia Mayumi Ogochi Kamiya | Chief Executive Officer | 0 companies |
| Niklas Kruse | Confidential Clerk | 0 companies |
| Matheus Barbosa Vieira | Chief Executive Officer | 0 companies |
| Tuula Margit Raussi | Confidential Clerk | 0 companies |
| Elisa Maritta Lintunen | Confidential Clerk | 0 companies |
| Anna-Kaarina Järvinen | Confidential Clerk | 0 companies |
| Matheus Barbosa Vieira | Chief Executive Officer | 0 companies |
| Timo Juhani Niskanen | Chief Executive Officer | 0 companies |
| Henna Mielikki Saarialho-Kahila | Confidential Clerk | 0 companies |
| Josef Joachim Bäckström | Confidential Clerk | 0 companies |
| Tiina Maria Korpelainen | Confidential Clerk | 0 companies |
| Michael Dr Heuer | Board of Directors | 0 companies |
| David Daniel Thomas Traub | Board of Directors | 0 companies |
| Bernard Maurice Georges Colombo | Board of Directors | 0 companies |
| Maturin Tchoumi | Chairperson | 0 companies |
| Esther Regina de Rooij | Chairperson | 0 companies |
| Julia Eva Kerstin Fichter | Board of Directors | 0 companies |
| Lisa Slater | Board of Directors | 0 companies |